Suppr超能文献

一种可修饰的通用细胞角蛋白嵌合抗原系统的 NK 细胞,具有多个靶点。

A modifiable universal cotinine-chimeric antigen system of NK cells with multiple targets.

机构信息

Immunotherapy Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Yuseong-gu, Daejeon, Republic of Korea.

Research Center for Bioconvergence Analysis, Korea Basic Science Institute, Cheongju-si, Chungcheonbuk-do, Republic of Korea.

出版信息

Front Immunol. 2023 Jan 13;13:1089369. doi: 10.3389/fimmu.2022.1089369. eCollection 2022.

Abstract

Natural killer (NK) cells are immune effector cells with outstanding features for adoptive immunotherapy. Immune effector cells with chimeric antigen receptors (CARs) are promising targeted therapeutic agents for various diseases. Because tumor cells exhibit heterogeneous antigen expression and lose cell surface antigen expression during malignant progression, many CARs fixed against only one antigen have limited efficacy and are associated with tumor relapse. To expand the utility of CAR-NK cells, we designed a split and universal cotinine-CAR (Cot-CAR) system, comprising a Cot-conjugator and NK92 cells (α-Cot-NK92 cells) engineered with a CAR containing an anti-Cot-specific single-chain variable fragment and intracellular signaling domain. The efficacy of the Cot-CAR system was assessed using a cytolysis assay against various tumor cells, and its single- or multiple- utility potential was demonstrated using an lung metastasis model by injecting A549-Red-Fluc cells. The α-Cot-NK92 cells could switch targets, logically respond to multiple antigens, and tune cytolytic activation through the alteration of conjugators without re-engineering. Therefore the universal Cot-CAR system is useful for enhancing specificity and diversity of antigens, combating relapse, and controlling cytolytic activity. In conclusion, this universal Cot-CAR system reveals that multiple availability and controllability can be generated with a single, integrated system.

摘要

自然杀伤 (NK) 细胞是具有出色特点的免疫效应细胞,适合用于过继免疫治疗。嵌合抗原受体 (CAR) 的免疫效应细胞是治疗各种疾病的有前途的靶向治疗药物。由于肿瘤细胞表现出异质性抗原表达,并且在恶性进展过程中丧失细胞表面抗原表达,因此许多仅针对一种抗原的 CAR 疗效有限,并与肿瘤复发相关。为了扩大 CAR-NK 细胞的用途,我们设计了一个分裂和通用的可替宁-CAR(Cot-CAR)系统,包括一个 Cot 缀合物和用包含抗 Cot 特异性单链可变片段和细胞内信号结构域的 CAR 工程改造的 NK92 细胞(α-Cot-NK92 细胞)。使用细胞溶解测定法评估了 Cot-CAR 系统对各种肿瘤细胞的疗效,并通过注射 A549-Red-Fluc 细胞在肺转移模型中证明了其单一或多种用途的潜力。α-Cot-NK92 细胞可以切换靶标,通过改变缀合物而无需重新设计,逻辑上对多种抗原作出反应,并调整细胞溶解激活。因此,通用的 Cot-CAR 系统有助于增强抗原的特异性和多样性,对抗复发,并控制细胞溶解活性。总之,这个通用的 Cot-CAR 系统表明,单个集成系统可以产生多种可用性和可控性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验